BeiGene Ltd ADR (NASDAQ:BGNE)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - BGNE

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - BGNE

  • Market Cap$12.608bn
  • SymbolNASDAQ:BGNE
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS07725L1026

Company Profile

BeiGene Ltd is a United States based clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.BeiGene Ltd is a biopharmaceutical company engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-A317 and BGB-290 and one immuno-oncology agent.

Latest BGNE news

Currently there for this company. Visit our news hub for other news .